Provided by the present invention are methods of treating a variety of disorders including AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), antibiotic induced diarrheal diseases (Clostridium difficile), multiple sclerosis, osteoporosis, gingivitis, peptic ulcer disease, esophagitis, diabetes, retinitis, uveitis, reperfusion injury after myocardial infarction (MI) or cerebral vascular accident (CVA), aphthous ulcers (oral), atherosclerosis (plaque rupture), prevention of tumor metastases, asthma, preeclampsia, and allergic disorders such as rhinitis, conjunctivitis, and urticaria.

Genetics Institute, Inc.

Method of using IL-11 for treating antibiotic induced diarrhea

A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula ##STR1##or a pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R.sub.3, R.sub.4, and R.sub.5 are as defined herein.

Pfizer Inc

Corticotropin releasing factor antagonists

This invention offers capsules for oral preparation which is useful for colon diseases such as colon cancer, ulcerative colitis, constipation and diarrhea and for systemic diseases such as osteoporosis and which does not undergo any change at all in stomach and in small intestine but firstly start to disintegrate upon arriving at large intestine and, at the same time, quickly release the drug therefrom wherein the capsule base therefor is hydroxypropylmethylcellulose (HPMC) or polyethyleneglycol-compounded HPMC, gelatin or agar and, on the surface of said capsule base in which powder or liquid containing a pharmacologically active substance is encapsulated, a double-coated structure comprising an inner layer consisting of a cationic copolymer and an outer layer consisting of anionic copolymer is formed.

Hisamitsu Pharmaceutical Co., Inc.

Capsules for oral preparations and capsule preparations for oral administration

This invention relates to compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein: A, B, R.sup.1, R.sup.2 and R.sup.3 are each as described herein, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by CB2 receptor binding activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma, dermatitis, seasonal allergic rhinitis, gastroesophageal reflux disease (GERD), constipation, diarrhea, functional gastrointestinal disorder, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, psoriasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glomerulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasculitis, myocardial infarction, cerebral ischemia, reversible airway obstruction, adult respiratory disease syndrome, chronic obstructive pulmonary disease (COPD), cryptogenic fibrosing alveolitis or bronchitis. ##STR00001##

Pfizer Inc.

Benzimidazolone derivatives as CB2 receptor ligands

This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma, dermatitis, seasonal allergic rhinitis, GERD, constipation, diarrhea, functional gastrointestinal disorders, irritable bowel syndrome, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, psoriasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glomerulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasculitis, myocardial infarction, cerebral ischemia, reversible airway obstruction, adult respiratory disease syndrome, COPD, cryptogenic fibrosing alveolitis and bronchitis. ##STR00001##

osteoporosis/kuhara

Method of using IL-11 for treating antibiotic induced diarrhea

Corticotropin releasing factor antagonists

Capsules for oral preparations and capsule preparations for oral administration

Benzimidazolone derivatives as CB2 receptor ligands

Sulfonyl benzimidazole derivatives

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi